Pauline A. Flanagan

TL;DR: These macromolecular produgs have the ability to concentrate drug in solid tumours, and with incorporation of targeting residues can promote organ-specific or tumour-specific uptake, and covalent conjugation markedly reduces all aspects of DOX-associated toxicity.

TL;DR: It was found that free drug at equivalent dose was also effective against Walker sarcoma in vivo and the therapeutic index of polymer conjugated drug was not appreciably greater than that of the free drug and was dependent on the dosing regime.

TL;DR: Conjugates designed to maintain immunoreactivity following linkage through oxidised carbohydrates are currently being synthesised, Nevertheless, the conjugates display increased rates of extravasation, compared with proteins of the same hydrodynamic size, and the decreased charge is anticipated to accelerate diffusion through tumour interstitium.

TL;DR: The transferrin receptor of human skin fibroblasts was studied as an in vitro model target antigen receptor for interaction with protein-polymer conjugates having potential for targeted drug delivery and implications regarding clinical potential of protein-HPMA copolymer conjUGates designed for lysosomotropic drug delivery are presented.

TL;DR: Two proteins (model targeting residues) human immunoglobulin fraction (IgG) and human transferrin have been conjugated to N-(2-hydroxy propyl)methacrylamide (HPMA) copolymer and the antibody titer elicited, after subcutaneous or intraperitoneal administration to A/J and B10 mice of free and conjugate protein, was measured using the ELISA technique.